Tjebo F C Heeren

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/142108/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Macular telangiectasia type 2. Progress in Retinal and Eye Research, 2013, 34, 49-77.	7.3	311
2	Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy. New England Journal of Medicine, 2019, 381, 1422-1433.	13.9	166
3	Nitroglycerin-Induced Endothelial Dysfunction and Tolerance Involve Adverse Phosphorylation and <i>S</i> -Glutathionylation of Endothelial Nitric Oxide Synthase. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2223-2231.	1.1	92
4	Vascular Dysfunction in Experimental Diabetes Is Improved by Pentaerithrityl Tetranitrate but Not Isosorbide-5-Mononitrate Therapy. Diabetes, 2011, 60, 2608-2616.	0.3	86
5	Progression of Vision Loss in Macular Telangiectasia Type 2. , 2015, 56, 3905.		64
6	LONGITUDINAL CORRELATION OF ELLIPSOID ZONE LOSS AND FUNCTIONAL LOSS IN MACULAR TELANGIECTASIA TYPE 2. Retina, 2018, 38, S20-S26.	1.0	58
7	CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2. Retina, 2018, 38, S8-S13.	1.0	51
8	Estimating Retinal Sensitivity Using Optical Coherence Tomography With Deep-Learning Algorithms in Macular Telangiectasia Type 2. JAMA Network Open, 2019, 2, e188029.	2.8	51
9	Validation of automated artificial intelligence segmentation of optical coherence tomography images. PLoS ONE, 2019, 14, e0220063.	1.1	48
10	Safety and Feasibility of a Novel Sparse Optical Coherence Tomography Device for Patient-Delivered Retina Home Monitoring. Translational Vision Science and Technology, 2018, 7, 8.	1.1	44
11	Vascular Dysfunction in Streptozotocin-Induced Experimental Diabetes Strictly Depends on Insulin Deficiency. Journal of Vascular Research, 2011, 48, 275-284.	0.6	43
12	VERY EARLY DISEASE MANIFESTATIONS OF MACULAR TELANGIECTASIA TYPE 2. Retina, 2016, 36, 524-534.	1.0	40
13	Effect of Face-Down Positioning vs Support-the-Break Positioning After Macula-Involving Retinal Detachment Repair. JAMA Ophthalmology, 2020, 138, 634.	1.4	38
14	Hyperglycemia and oxidative stress in cultured endothelial cells – a comparison of primary endothelial cells with an immortalized endothelial cell line. Journal of Diabetes and Its Complications, 2012, 26, 155-162.	1.2	37
15	FIRST SYMPTOMS AND THEIR AGE OF ONSET IN MACULAR TELANGIECTASIA TYPE 2. Retina, 2014, 34, 916-919.	1.0	37
16	Macular Telangiectasia Type 2: Visual Acuity, Disease End Stage, and the MacTel Area. Ophthalmology, 2020, 127, 1539-1548.	2.5	34
17	α1AMP-Activated Protein Kinase Mediates Vascular Protective Effects of Exercise. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1632-1641.	1.1	32
18	Quantification of Key Retinal Features in Early and Late Age-Related Macular Degeneration Using Deep Learning. American Journal of Ophthalmology, 2021, 226, 1-12.	1.7	32

TJEBO F C HEEREN

#	Article	IF	CITATIONS
19	Right-angled vessels in macular telangiectasia type 2. British Journal of Ophthalmology, 2021, 105, 1289-1296.	2.1	30
20	Diagnostic accuracy of diabetic retinopathy grading by an artificial intelligence-enabled algorithm compared with a human standard for wide-field true-colour confocal scanning and standard digital retinal images. British Journal of Ophthalmology, 2021, 105, 265-270.	2.1	29
21	High-Performance Virtual Reality Volume Rendering of Original Optical Coherence Tomography Point-Cloud Data Enhanced With Real-Time Ray Casting. Translational Vision Science and Technology, 2018, 7, 2.	1.1	28
22	POOR LONG-TERM OUTCOME OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2. Retina, 2015, 35, 2619-2626.	1.0	26
23	Pentaerythritol Tetranitrate In Vivo Treatment Improves Oxidative Stress and Vascular Dysfunction by Suppression of Endothelin-1 Signaling in Monocrotaline-Induced Pulmonary Hypertension. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-13.	1.9	26
24	Identification of genetic factors influencing metabolic dysregulation and retinal support for MacTel, a retinal disorder. Communications Biology, 2021, 4, 274.	2.0	26
25	Systemic lipid dysregulation is a risk factor for macular neurodegenerative disease. Scientific Reports, 2020, 10, 12165.	1.6	24
26	Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2. Acta Ophthalmologica, 2019, 97, e998-e1005.	0.6	22
27	Macular Pigment Distribution as Prognostic Marker for Disease Progression in Macular Telangiectasia Type 2. American Journal of Ophthalmology, 2018, 194, 163-169.	1.7	19
28	In-vivo mapping of drusen by fundus autofluorescence and spectral-domain optical coherence tomography imaging. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 59-67.	1.0	18
29	Quantification of Retinal and Choriocapillaris Perfusion in Different Stages of Macular Telangiectasia Type 2. , 2019, 60, 3556.		18
30	ELECTROPHYSIOLOGICAL CHARACTERIZATION OF MACULAR TELANGIECTASIA TYPE 2 AND STRUCTURE–FUNCTION CORRELATION. Retina, 2018, 38, S33-S42.	1.0	15
31	Enhanced resolution and speckleâ€free threeâ€dimensional printing of macular optical coherence tomography angiography. Acta Ophthalmologica, 2019, 97, e317-e319.	0.6	14
32	HYPERREFLECTIVITY ON OPTICAL COHERENCE TOMOGRAPHY IN MACULAR TELANGIECTASIA TYPE 2. Retina, 2021, 41, 1428-1437.	1.0	14
33	SCOTOMA CHARACTERISTICS IN MACULAR TELANGIECTASIA TYPE 2. Retina, 2018, 38, S14-S19.	1.0	13
34	Binocular Inhibition of Reading in Macular Telangiectasia Type 2. , 2019, 60, 3835.		13
35	Contrast sensitivity and visual acuity under low light conditions in macular telangiectasia type 2. British Journal of Ophthalmology, 2019, 103, 398-403.	2.1	12
36	Dark-Adapted Two-Color Fundus-Controlled Perimetry in Macular Telangiectasia Type 2. , 2019, 60, 1760.		11

TJEBO F C HEEREN

#	Article	IF	CITATIONS
37	Novel biomarker of sphericity and cylindricity indices in volume-rendering optical coherence tomography angiography in normal and diabetic eyes: a preliminary study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 711-723.	1.0	11
38	Feasibility of support vector machine learning in ageâ€related macular degeneration using small sample yielding sparse optical coherence tomography data. Acta Ophthalmologica, 2019, 97, e719-e728.	0.6	10
39	Comparison of true-colour wide-field confocal scanner imaging with standard fundus photography for diabetic retinopathy screening. British Journal of Ophthalmology, 2020, 104, bjophthalmol-2019-315269.	2.1	10
40	Treatment for Macular Telangiectasia Type 2. Developments in Ophthalmology, 2016, 55, 189-195.	0.1	9
41	Fundus Autofluorescence Imaging in Macular Telangiectasia Type 2: MacTel Study Report Number 9. American Journal of Ophthalmology, 2021, 228, 27-34.	1.7	9
42	Postretinal Detachment Retinal Displacement: How Best to Detect It?. Ophthalmologica, 2020, 243, 280-287.	1.0	8
43	Longitudinal Assessment of Remnant Foveal Cone Structure in a Case Series of Early Macular Telangiectasia Type 2. Translational Vision Science and Technology, 2020, 9, 27.	1.1	8
44	Effect of ethnicity and other sociodemographic factors on attendance at diabetic eye screening: a 12-month retrospective cohort study. BMJ Open, 2021, 11, e046264.	0.8	8
45	DARK ADAPTATION IN MACULAR TELANGIECTASIA TYPE 2. Retina, 2020, 40, 2018-2025.	1.0	7
46	MACULAR TELANGIECTASIA TYPE 2. Retina, 2018, 38, S97-S104.	1.0	6
47	Contextualizing singleâ€arm trials with realâ€world data: An emulated target trial comparing therapies for neovascular ageâ€related macular degeneration. Clinical and Translational Science, 2021, 14, 1166-1175.	1.5	4
48	Intraretinal pigmented cells in retinal degenerative disease. British Journal of Ophthalmology, 2023, 107, 1736-1743.	2.1	4
49	EFFECT OF DARK ADAPTATION AND BLEACHING ON BLUE LIGHT REFLECTANCE IMAGING IN MACULAR TELANGIECTASIA TYPE 2. Retina, 2018, 38, S89-S96.	1.0	3
50	High-Resolution In Vivo Fundus Angiography using a Nonadaptive Optics Imaging System. Translational Vision Science and Technology, 2019, 8, 54.	1.1	3
51	Stereoscopic Vision in Macular Telangiectasia Type 2. Ophthalmologica, 2019, 241, 121-129.	1.0	3
52	IDENTIFICATION OF INCREASED BLUE LIGHT REFLECTIVITY IN MACULAR TELANGIECTASIA TYPE 2 USING SCANNING LASER OPHTHALMOSCOPY VERSUS RED-FREE FUNDUS PHOTOGRAPHY. Retinal Cases and Brief Reports, 2019, 13, 115-117.	0.3	1
53	Vascular Dysfunction in Streptozotocininduced Experimental Diabetes Strictly Depends on Insulin Deficiency. Free Radical Biology and Medicine, 2010, 49, S38.	1.3	0

54 Macular Telangiectasia Type 2. , 2014, , 111-118.

#	Article	IF	CITATIONS
55	Feasibility Study of Subfoveal Choroidal Thickness Changes in Spectral-Domain Optical Coherence Tomography Measurements of Macular Telangiectasia Type 2. Lecture Notes in Computer Science, 2018, , 303-309.	1.0	0
56	State of the art spatial visualization of the response of neovascularisation to anti-vascular endothelial growth factor therapy, American Journal of Ophthalmology Case Reports, 2022, 25, 101267	0.4	0

endothelial growth factor therapy. American Journal of Ophthalmology Case Reports, 2022, 25, 101267.